データ種別 | 図書 |
---|---|
出版者 | Philadelphia : Wolters Kluwer Health/Lippincott Williams & Wilkins |
出版年 | c2011 |
著者標目 | Das, Arup Friberg, Thomas |
配架場所 | 巻 次 | 請求記号 | 登録番号 | 状 態 | コメント | ISBN | 刷 年 | 予約 | 利用注記 |
---|---|---|---|---|---|---|---|---|---|
IPE 図書 |
|
WW140||D229t||2011 | 41048922 |
|
9781605476407 |
|
|
大きさ | p. ; cm |
---|---|
件 名 | LCSH:Eye -- Blood-vessels -- Diseases -- Chemotherapy LCSH:Neovascularization MESH:Eye Diseases -- drug therapy MESH:Angiogenesis Inhibitors -- therapeutic use MESH:Eye -- blood supply MESH:Neovascularization, Pathologic -- drug therapy MESH:Neovascularization, Pathologic -- physiopathology |
一般注記 | Includes bibliographical references and index Summary: "Ocular angiogenesis, or the abnormal growth of blood vessels in the eye, is the cause of major neovascular eye diseases. In addition, retinal and choroidal neovascularization are the major causes of vision loss in this country. With the new era of anti-angiogenic therapies already in practice, ophthalmologists have started treating many ocular diseases including macular degeneration, diabetic retinopathy, and retinal vascular occlusion using anti-angiogenic drugs. This book covers the basic pathophysiology of ocular angiogenesis and strategies for inhibition. The authors discuss the "Principles" of anti-angiogenic therapy, pre-clinical studies, future drugs on the horizon, drug delivery, and the "Practice" of the therapy in many ocular diseases. Vision researchers in both academia and industry, as well as clinician scientists, have contributed chapters on different aspects of the angiogenic process, and clinical strategies to fight it. The book also includes chapters that deal with diabetic macular |
分 類 | LCC:RE720 NLM:WW 140 DC22:616.99/484 |
書誌ID | BB10100001 |
本文言語 | 英語 |
巻冊次 | : alk. paper ; ISBN:9781605476407 |
NCID | GB56239792 |
図書館サービス